Focal versus whole-gland radiation boost for localized prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This trial compares two ways of giving a radiation boost (brachytherapy) to the prostate for men with localized prostate cancer. One method targets only the visible tumor, while the other treats the whole gland, and the study aims to see if the focal approach works as well with fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with prostate cancer (confirmed by biopsy).
- Your cancer is considered intermediate or high risk with features like a tumor stage cT1 or cT2a, a Gleason grade group of 2–4, and a PSA of 20 or lower.
- An MRI (mpMRI) shows a visible suspicious area (PI-RADS 3–5) in the prostate.
- Your prostate is not too large (usually 60 cc or less; up to 80 cc if urinary symptoms are mild).
- You have not had prior pelvic radiation or recent prostate surgery (like TURP, prostatectomy, or HIFU) within the last 6 months.
- You are able to undergo general anesthesia and lie flat for radiation treatment planning.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two ways of giving radiation to the prostate, including a “boost” using a special internal radiation treatment. It’s meant to see which radiation schedule works better and is safer for certain prostate cancer patients.
This trial studies whether giving a moderate “boost” dose of radiation to the prostate—along with radiation to the pelvic area—can better control high-risk localized prostate cancer. You may benefit if you have high-risk disease and can safely receive radiation.
This trial tests whether giving higher radiation doses to the prostate and pelvic lymph nodes is more effective than treating only the prostate. You may benefit if your prostate cancer has spread to nearby lymph nodes but not to bones or other organs, and you are getting hormone therapy.
This trial tests a newer, more precise radiation treatment that gives a higher dose to the main tumor while keeping radiation to the rest of the prostate the same. It is for men with intermediate- or high-risk prostate cancer who haven't had prior prostate radiation or removal.
This trial tests whether adding an extra, focused dose of radiation to the visible tumor during MRI-guided radiotherapy can better treat locally advanced prostate cancer. It aims to improve cancer control while limiting side effects.
This study tests adding a targeted “boost” of HDR (high-dose-rate) internal radiation to the prostate along with standard external beam radiation. It may help improve cancer control while keeping the treatment focused on the area seen on scans and biopsy.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.